The role of diabetes co-morbidity for tuberculosis treatment outcomes: a prospective cohort study from Mwanza, Tanzania

BMC Infectious Diseases

Henrik Friis⁷  Åse Bengård Andersen⁵  Daniel Rinse Witte⁴  Henrik Krarup¹  Torben Martinussen⁶  Dirk Lund Christensen⁴  John Changalucha³  Martine Grosos Aabye²  Maria Faurholt-Jepsen⁷  Jeremiah Kidola³  George Praygod³  Nyagosya Range⁸  Daniel Faurholt-Jepsen⁷ 

[1] Department of Clinical Biochemistry, Aalborg University Hospital, Aalborg, Denmark;Clinical Research Centre, University of Copenhagen, Hvidovre Hospital, Hvidovre, Denmark;Mwanza Medical Centre, National Institute of Medical Research, Mwanza, Tanzania;Steno Diabetes Center, Gentofte, Denmark;Department of Infectious Diseases, Odense University Hospital, Odense, Denmark;Department of Basic Sciences and Environment, University of Copenhagen, Frederiksberg, Denmark;Department of Human Nutrition, University of Copenhagen, Frederiksberg, Denmark;Muhimbili Medical Centre, National Institute of Medical Research, Dar Es Salaam, Tanzania

关键词: Grip strength;    Haemoglobin;    Anthropometry;    Treatment outcome;    Diabetes;    Tuberculosis;   

Others  :  1175326
DOI  :  10.1186/1471-2334-12-165

 received in 2012-03-30, accepted in 2012-07-16,  发布年份 2012

【 摘 要 】

Background

Due to the association between diabetes and pulmonary tuberculosis (TB), diabetes may threaten the control of TB. In a prospective cohort study nested in a nutrition trial, we investigated the role of diabetes on changes in anthropometry, grip strength, and clinical parameters over a five months follow-up period.

Methods

Among pulmonary TB patients with known diabetes status, we assessed anthropometry and clinical parameters (e.g. haemoglobin) at baseline and after two and five months of TB treatment. A linear mixed-effects model (repeated measurements) was used to investigate the role of diabetes during recovery.

Results

Of 1205 TB patients, the mean (standard deviation) age was 36.6 (13.0) years, 40.9% were females, 48.9% were HIV co-infected, and 16.3% had diabetes. TB patients with diabetes co-morbidity experienced a lower weight gain at two (1.3 kg, CI95% 0.5; 2.0, p = 0.001) and five months (1.0 kg, CI95% 0.3; 1.7, p = 0.007). Similarly, the increase in the level of haemoglobin was lower among TB patients with diabetes co-morbidity after two (Δ 0.6 g/dL, CI95% 0.3; 0.9 p < 0.001) and five months (Δ 0.5 g/dL, CI95% 0.2; 0.9 p = 0.004) of TB treatment, respectively.

Conclusion

TB patients initiating TB treatment with diabetes co-morbidity experience delayed recovery of body mass and haemoglobin, which are important for the functional recovery from disease.

【 授权许可】

   
2012 Faurholt-Jepsen et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

【 参考文献 】

• [1]Jeon CY, Murray MB: Diabetes mellitus increases the risk of active tuberculosis: a systematic review of 13 observational studies. PLoS Med 2008, 5:e152.
• [2]Wild S, Roglic G, Green A, Sicree R, King H: Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 2004, 27:1047-1053.
• [3]Güler M, Ünsal E, Dursun B, AydIn Ö, Capan N: Factors influencing sputum smear and culture conversion time among patients with new case pulmonary tuberculosis. Int J Clin Pract 2007, 61:231-235.
• [4]Dooley KE, Tang T, Golub JE, Dorman SE, Cronin W: Impact of Diabetes Mellitus on Treatment Outcomes of Patients with Active Tuberculosis. AmJTrop Med Hyg 2009, 80:634-639.
• [5]Wang CS, Yang CJ, Chen HC, Chuang SH, Chong IW, Hwang JJ, Huang MS: Impact of type 2 diabetes on manifestations and treatment outcome of pulmonary tuberculosis. Epidemiol Infect 2009, 137:203-210.
• [6]Sasaki Y, Yamagishi F, Yagi T, Itakura M, Fujikawa A, Kuga M, Ishimaru T: A study on pulmonary tuberculosis retreatment cases. Kekkaku 2003, 78:723-732.
• [7]PrayGod G, Range N, Faurholt-Jepsen D, Jeremiah K, Faurholt-Jepsen M, Aabye MG, Jensen L, Jensen AV, Grewal HMS, Magnussen P, Changalucha J, Andersen AB, Friis H: Weight, body composition and handgrip strength among pulmonary tuberculosis patients: a matched cross-sectional study in Mwanza, Tanzania. Trans. R. Soc. Trop. Med. Hyg 2011, 105:140-147.
• [8]Dulloo AG, Jacquet J, Montani J-P: Pathways from weight fluctuations to metabolic diseases: focus on maladaptive thermogenesis during catch-up fat. Int. J. Obes. Relat. Metab. Disord. 2002, 26(2):46-57.
• [9]Walter T, Olivares M, Pizarro F, Muñoz C: Iron, Anemia, and Infection. Nutr Rev 1997, 55:111-124.
• [10]PrayGod G, Range N, Faurholt-Jepsen D, Jeremiah K, Faurholt-Jepsen M, Aabye MG, Jensen L, Jensen AV, Grewal HMS, Magnussen P, Changalucha J, Andersen AB, Friis H: Daily Multi-Micronutrient Supplementation during Tuberculosis Treatment Increases Weight and Grip Strength among HIV-Uninfected but Not HIV-Infected Patients in Mwanza, Tanzania. J Nutr 2011, 141:685-691.
• [11]Global tuberculosis control: a short update to the 2009 report. http://www.who.int/tb/publications/global_report/2009/update/en/index.html webcite
• [12]Whiting DR, Guariguata L, Weil C, Shaw J: IDF Diabetes Atlas: Global estimates of the prevalence of diabetes for 2011 and 2030. Diabetes Research and Clinical Practice 2011, 94:311-321.
• [13]Chonde TM, Basra D, Mfinanga SGM, Range N, Lwilla F, Shirima RP, van Deun A, Zignol M, Cobelens FG, Egwaga SM, van Leth F: National anti-tuberculosis drug resistance study in Tanzania. Int. J. Tuberc. Lung Dis. 2010, 14:967-972.
• [14]Range N, Magnussen P, Mugomela A, Malenganisho W, Changalucha J, Temu MM, Mngara J, Krarup H, Friis H, Andersen ÅB: HIV and parasitic co-infections in tuberculosis patients: a cross-sectional study in Mwanza, Tanzania. Ann Trop Med Parasitol 2007, 101:343-351.
• [15]Faurholt-Jepsen D, Range N, Praygod G, Jeremiah K, Faurholt-Jepsen M, Aabye MG, Changalucha J, Christensen DL, Pipper CB, Krarup H, Witte DR, Andersen AB, Friis H: Diabetes is a risk factor for pulmonary tuberculosis: a case–control study from mwanza. Tanzania. PLoS ONE 2011, 6:e24215.
• [16]Faurholt‒Jepsen D, Range N, PrayGod G, Jeremiah K, Faurholt‒Jepsen M, Aabye MG, Changalucha J, Christensen DL, Krarup H, Witte DR, Andersen AB, Friis H: The role of diabetes on the clinical manifestations of pulmonary tuberculosis. Tropical Medicine & International Health 2012, 17:877-883.
• [17]Treatment of Tuberculosis: guidelines for national programmes. http://www.who.int/tb/publications/tb_treatmentguidelines/en/index.html webcite
• [18]Praygod G, Range N, Faurholt-Jepsen D, Jeremiah K, Faurholt-Jepsen M, Aabye MG, Jensen L, Jensen AV, Grewal HMS, Magnussen P, Changalucha J, Andersen AB, Friis H: The effect of energy-protein supplementation on weight, body composition and handgrip strength among pulmonary tuberculosis HIV-co-infected patients: randomised controlled trial in Mwanza, Tanzania. Br J Nutr 2012, 107:1-9.
• [19]IUATLD: Technical guide: sputum examination for tuberculosis by direct microscopy in low income countries. Paris: 5th edition. International Union Against Tuberculosis and Lung Disease (IUATLD); 2000.
• [20]Frisancho AR: Anthropometric standards for the assessment of growth and nutritional status. Ann Arbor: The University of Michigan Press; 1990.
• [21]Gearhart MM, Parbhoo SK: Hyperglycemia in the critically ill patient. AACN Clin Issues 2006, 17:50-55.
• [22]Başoğlu OK, Bacakoğlu F, Cok G, Sayiner A, Ateş M: The oral glucose tolerance test in patients with respiratory infections. Monaldi Arch Chest Dis 1999, 54:307-310.
• [23]WHO: Definition and diagnosis of diabetes mellitus and intermediate hyperglycaemia. Geneva, Switzerland: WHO Press; 2006.
• [24]Fitzmaurice GM, Laird NM, Ware JH: Applied Longitudinal Analysis. 2nd edition. Hoboken, New Jersey: Wiley; 2011.
• [25]Kreuzer K-A, Rockstroh JK: Pathogenesis and pathophysiology of anemia in HIV infection. Ann Hematol 1997, 75:179-187.
• [26]Collins S, Myatt M, Golden B: Dietary treatment of severe malnutrition in adults. Am J Clin Nutr 1998, 68:193-199.
• [27]Marchesini G, Forlani G, Zoli M, Vannini P, Pisi E: Muscle protein breakdown in uncontrolled diabetes as assessed by urinary 3-methylhistidine excretion. Diabetologia 1982, 23:456-458.
• [28]Nair G, Sainani GS, Krishnaswamy PR: Evidence of glycosylation of platelet proteins in diabetics. J Assoc Physicians India 1985, 33:299-300.
• [29]Andersen AB, Range NS, Changalucha J, PrayGod G, Kidola J, Faurholt-Jepsen D, Krarup H, Grewal H, Friis H: CD4 lymphocyte dynamics in Tanzanian pulmonary tuberculosis patients with and without HIV co-infection. BMC Infect Dis 2012, 12:66. BioMed Central Full Text